

Sister Study First DCIS or Invasive Breast Cancer Events ¹ Stratified by Race/Ethnicity ²: Data Release 10.1 ³

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,671)	%	N (total = 364)	%	N (total = 256)	%
Breast Cancer Subtype for 1st DCIS or Invasive Diagnosis						
Invasive ⁴	2,909	79.2	271	74.5	212	82.8
Ductal only (no lobular component) ⁵	2,038	55.5	169	46.4	155	60.5
Lobular only (no ductal component) ⁵	270	7.4	13	3.6	14	5.5
Ductal and lobular ^{5,6}	203	5.5	9	2.5	14	5.5
Inflammatory	6	0.2	2	0.5	0	0.0
Paget's	10	0.3	2	0.5	0	0.0
Phyllodes ⁷	5	0.1	0	0.0	0	0.0
Other/unknown if ductal or lobular ⁸	377	10.3	76	20.9	29	11.3
<i>In situ</i>	753	20.5	93	25.5	43	16.8
Ductal only (no lobular component) ⁹	732	19.9	91	25.0	43	16.8
Ductal and lobular ^{6,9}	16	0.4	0	0.0	0	0.0
Paget's	5	0.1	0	0.0	0	0.0
Other ¹⁰	0	0.0	2	0.5	0	0.0
Invasiveness unknown ¹¹	9	0.2	0	0.0	1	0.4
Stage at 1st DCIS or Invasive Diagnosis ¹²						
0	700	21.4	75	27.6	41	18.3
I	1,738	53.2	113	41.5	114	50.9
II	647	19.8	66	24.3	47	21.0
III	160	4.9	18	6.6	20	8.9
IV	20	0.6	0	0.0	2	0.9
<i>Unknown, missing, cannot stage</i>	406		92		32	
Estrogen Receptor (ER) Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	2,748	85.8	196	75.4	179	83.6
Negative	449	14.0	62	23.8	35	16.4
Borderline	5	0.2	2	0.8	0	0.0
<i>Unknown, missing, not performed</i>	469		104		42	
Progesterone Receptor (PR) Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	2,311	74.3	149	59.1	146	69.5
Negative	795	25.5	102	40.5	64	30.5
Borderline	6	0.2	1	0.4	0	0.0
<i>Unknown, missing, not performed</i>	559		112		46	

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,671)	%	N (total = 364)	%	N (total = 256)	%
HER2 Amplification Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	327	12.2	33	16.0	34	17.8
Negative	2,311	86.4	172	83.5	155	81.2
Borderline	38	1.4	1	0.5	2	1.0
<i>Unknown, missing, not performed</i>	995		158		65	
Combined ER, PR, HER2 Status: 1st DCIS or Invasive Breast Cancer ¹²						
Triple negative (ER-, PR-, and HER2-)	241	7.8	42	16.7	18	8.7
Not triple negative	2,867	92.2	210	83.3	190	91.3
<i>Unknown, missing, not performed</i>	563		112		48	
Diagnosis Confirmation ¹³						
Medical	3,104	84.6	247	67.9	212	82.8
NDI Plus or death certificate	31	0.8	12	3.3	2	0.8
None	536	14.6	105	28.8	42	16.4
Age (in years) at 1st DCIS or Invasive Breast Cancer ¹⁴						
Under 50	323	8.8	50	13.7	34	13.3
50-64	1,604	43.7	173	47.5	148	57.8
65 and older	1,744	47.5	141	38.7	74	28.9
Menopausal Status at 1st DCIS or Invasive Breast Cancer						
Pre-menopausal	533	14.5	63	17.3	53	20.7
Post-menopausal	3,137	85.5	301	82.7	203	79.3
<i>Unknown</i>	1		0		0	

Abbreviations: DCIS=Ductal carcinoma *in situ*; BrCa= Breast cancer; MR = Medical report (medical record and/or pathology report)

¹ Breast cancer events (1st DCIS or invasive) are defined by the following ICD10 codes: D05.1 (ductal carcinoma *in situ*), C50 (all invasive breast cancer), and ductal D48.6 (neoplasm of uncertain behavior of breast)

² Excludes n=1 where race/ethnicity is missing

³ Data release 10.1 includes events from follow-up phases that closed **on or before 10/12/2020**, excluding any data from participants who have withdrawn their data from the study (n=4). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 10.1 breast cancer events for 1st DCIS or invasive diagnosis exclude a) through c) below:

- a) Breast cancers diagnosed prior to participant's baseline date;
- b) Breast cancers diagnosed with unknown timing relative to baseline;
- c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out

⁴ Includes 'presumed invasive' (i.e. a carcinoma *in situ* with positive nodes)

⁵ Ductal only, Lobular only, and Ductal and Lobular exclude inflammatory breast cancer and Paget's

- ⁶ Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g. a ductal only tumor and a lobular only tumor)
- ⁷ Phyllodes is neither ductal nor lobular; it is a sarcoma
- ⁸ Includes: a) Invasive but unknown if ductal or lobular, these are typically self-report without MR confirmation; b) Invasive type “neither ductal nor lobular, not otherwise specified”, these are typically self-report without MR confirmation; and c) Per MR, presumed invasive - *in situ* tumor, positive nodes
- ⁹ *In situ* Ductal only and *in situ* Ductal and Lobular exclude *in situ* Paget’s
- ¹⁰ Excludes all with lobular-only origin, these are typically self-report without MR confirmation
- ¹¹ Invasiveness unknown includes: a) Unknown if DCIS or invasive ductal; and b) Per MR, unable to determine if DCIS or atypical ductal hyperplasia
- ¹² Priority for stage and ER/PR/HER2 status when diagnosis is reported by multiple sources: Medical record>Breast Cancer Follow-Up Form
- ¹³ Medical confirmation of reported breast cancer is generally from medical records but may only include pathology report; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation
- ¹⁴ For those missing age at diagnosis, age was imputed as the midpoint of the range of plausible ages at diagnosis